The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer?

被引：159

作者：

Duffy M.J. ^{[1
,2
]}

Mullooly M. ^{[1
,2
]}

O'Donovan N. ^{[3
]}

Sukor S. ^{[2
,4
]}

Crown J. ^{[4
]}

Pierce A. ^{[1
,2
]}

McGowan P.M. ^{[1
,2
]}

机构：

[1] Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital

[2] UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin

[3] National Institute for Cellular Biotechnology, Dublin City University

[4] Department of Medical Oncology, St Vincent's University Hospital

来源：

Clinical Proteomics | 2011年 / 8卷 / 1期

关键词：

Breast Cancer; Trastuzumab; Lapatinib; GW2974; ADAM Protein;

D O I：

10.1186/1559-0275-8-9

中图分类号：

学科分类号：

摘要：

The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer. © 2011 Duffy et al; licensee BioMed Central Ltd.

引用

共 80 条

[31] McGowan P.M., McKiernan E., Bolster F., Ryan B.M., Hill A.D.K., Mcdermott E.W., Evoy D., O'Higgins N., Crown J., Duffy M.J., ADAM-17 predicts adverse outcome in patients with breast cancer, Annals of Oncology, 19, 6, pp. 1075-1081, (2008)
[32] Zhou B.-B.S., Peyton M., He B., Liu C., Girard L., Caudler E., Lo Y., Baribaud F., Mikami I., Reguart N., Yang G., Li Y., Yao W., Vaddi K., Gazdar A.F., Friedman S.M., Jablons D.M., Newton R.C., Fridman J.S., Minna J.D., Scherle P.A., Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer, Cancer Cell, 10, 1, pp. 39-50, (2006)
[33] Fridman J.S., Caulder E., Hansbury M., Liu X., Yang G., Wang Q., Lo Y., Zhou B.-B., Pan M., Thomas S.M., Grandis J.R., Zhuo J., Yao W., Newton R.C., Friedman S.M., Scherle P.A., Vaddi K., Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer, Clinical Cancer Research, 13, 6, pp. 1892-1902, (2007)
[34] Witters L., Scherle P., Friedman S., Synergistic Inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor, Cancer Res, 68, pp. 7083-7089, (2008)
[35] Sahin U., Weskamp G., Kelly K., Zhou H.-M., Higashiyama S., Peschon J., Hartmann D., Saftig P., Blobel C.P., Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands, Journal of Cell Biology, 164, 5, pp. 769-779, (2004)
[36] Sahin U., Blobel C.P., Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17, FEBS Letters, 581, 1, pp. 41-44, (2007)
[37] Horiuchi K., Le Gall S., Schulte M., Yamaguchi T., Reiss K., Murphy G., Toyama Y., Hartmann D., Saftig P., Blobel C.P., Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx, Molecular Biology of the Cell, 18, 1, pp. 176-188, (2007)
[38] Peeters M., Price T., Van Laethem J.L., Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today?, Oncologist, 14, pp. 29-39, (2009)
[39] Browne B.C., O'Brien N., Duffy M.J., HER-2 signaling and inhibition in breast cancer, Current Cancer Drug Ther, 9, pp. 419-438, (2009)
[40] Bublil E.M., Yarden Y., The EGF receptor family: Spearheading a merger of signaling and therapeutics, Current Opinion in Cell Biology, 19, 2, pp. 124-134, (2007)

← 1 2 3 4 5 6 7 8 →